Operating profit EBITDA: 4D Molecular Corp (FDMT)
The prospects for 4D Molecular Therapeutics (FDMT) depend on confirming the efficacy of vectors in treating ocular pathologies. On GURU.Markets, the EBITDA trend reflects that the indicator has reached the level of 0.00. 4D Molecular Therapeutics (FDMT) is implementing bioengineered viruses for precise drug delivery, while competent management ensures the transparency of trials in cardiology and ophthalmology using advanced capsid platforms.
Summary analytical data breakdowns for 4D Molecular Therapeutics, Inc. (FDMT)
- stock price and consensus target price:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt burden and liquidity indicators:
Debt to Equity 4D Molecular Therapeutics|FDMT - Long-Term Debt to Equity|Short-Term Debt to Capital 4DMT|FDMT - Company Aggregate Debts|Debt to Book Capitalization Ratio 4D Molecular Therapeutics|FDMT - Company Long-Term Loans and Borrowings|Company Current Liabilities 4D Molecular Therapeutics|Quick Liquidity Indicator 4dmoleculartherapeutics.com
- business earnings and investment ratios data:
FDMT - Profit After Payment of Taxes|Projected Future Earnings 4D Molecular Therapeutics|FDMT - Company Value to Net Income|Forward P/E Multiple 4dmoleculartherapeutics.com|FDMT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics|FDMT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) 4D Molecular Therapeutics|FDMT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months 4dmoleculartherapeutics.com|FDMT - Earnings per share trend in current year|Earnings growth forecast for next year 4D Molecular Therapeutics
- sales and revenue indicators:
Summary company analytics:4D Molecular Corp (FDMT)
This indicator measures net cash flow from operating activities, stripping out non-cash charges to reflect the business's actual ability to generate liquidity. The growth in EBITDA_Co monitoring for 4D Molecular Therapeutics (FDMT) confirms the effective monetization of its gene therapy platform through licensing agreements with big pharma, allowing the company to increase operating capital without incurring capital expenditures.
Analysis of competing companies
Tempus - Profit before payment of interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS - Operating profit EBITDA|Profit before interest, taxes and amortization RGEN|Avidity Biosciences Inc (RNA) - Operating profit EBITDA|Operating profit before deduction of amortization CRSP|Operating profit before deduction of amortization GeneDx Corp (WGS)|Operating profit EBITDA RARE|Profit before payment of interest, taxes and amortization BEAM (beamtx.com)|Profit before payment of interest, taxes and amortization Sarepta SRPT|Operating profit EBITDA Twist Bioscience Inc TWST|10x Genomics Corp - Operating profit EBITDA|NTLA: Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization Stoke Therapeutics STOK|Operating profit before deduction of amortization biolifesolutions.com|WVE - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Company profit before taxes, interest and amortization Sionna Pharma|Operating profit EBITDA Prime Medicine Bio (PRME)|Income before deduction of interest, taxes and amortization Taysha Gene Therapies|Operating profit EBITDA uniqure.com QURE|MGTX (MeiraGTx) - Profit before interest, taxes and amortization|RGNX: Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization Solid Bio SLDB|Ocugen Pharma (OCGN) - Operating profit EBITDA|PACB (Pacific Biosciences) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNTC|DSGN - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA Rocket Pharma (RCKT)|LXEO: Profit before interest, taxes and amortization|KRRO - Operating profit before deduction of amortization|Editas Medicine, Inc. - Operating profit EBITDA|silence-therapeutics.com (SLN) - Operating profit before deduction of amortization|PRQR - Company profit before taxes, interest and amortization|Codexis (CDXS) - Operating profit EBITDA|SGMO: Operating income before deduction of amortization|Operating profit EBITDA Nautilus Biotechnology Inc|Operating profit before deduction of amortization MGX (Metagenomi, Inc.)|Profit before payment of interest, taxes and amortization DTIL (precisionbiosciences.com)|Operating income before deduction of amortization GBIO|Operating profit EBITDA Boundless Bio Inc. BOLD|Profit before deduction of interest, taxes, depreciation and amortization Exicure Corp|IMNN - Operating profit EBITDA|Operating profit before amortization phiopharma.com|MBIO (Mustang Bio) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization RNAZ|Operating profit before deduction of amortization Bionano (BNGO)|Company profit before taxes, interest and amortization Applied DNA|Operating profit EBITDA bluebird bio, Inc (BLUE)|IPA - Operating profit before amortization|omegatherapeutics.com - Profit before payment of interest, taxes and amortization|Singular Genomics (OMIC) - Operating profit before amortization|RGLS - Operating profit EBITDA|SYRS: Operating profit EBITDA|Operating profit before amortization TBIO|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|Operating profit before amortization UBX (unitybiotechnology.com)
